

REMARKS

Consideration of the application as amended above is respectfully requested.

In the specification, the new paragraph to be inserted on page 1, line 4, was added after the “TITLE OF THE INVENTION” paragraph and before the “BACKGROUND OF INVENTION” paragraph on page 1, to provide the priority of the present application.

Claims 1 to 15 were pending in the International Application. Claim 5 was amended to correct an obvious typographical error. Claims 11-15 were cancelled, and new Claims 16-20 have been added. Presently Claims 1-10 and 16-20 are pending in the present application.

New Claim 16 has been added directed to a method of treating a disease mediated by the Cannabinoid-1 receptor in a human patient in need of such treatment comprising administration of a non-toxic, therapeutically effective amount of a compound according to Claim 1. Support for Claim 16 is found in original “Swiss-style” use Claim 11, and in the specification, particularly at page 2, lines 14-15, and at page 13, lines 10-12.

New Claim 17 has been added directed to the method according to Claim 16, wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake. Support for Claim 17 is found in original “Swiss-style” use Claim 12, and in the specification, particularly at page 2, lines 16-28, and at page 13, lines 12-19.

New Claim 18 has been added directed to the method according to Claim 17 wherein the disease mediated by the Cannabinoid-1 receptor is selected from obesity, bulimia nervosa, and compulsive eating disorders. Support for Claim 18 is found in original “Swiss-style” use Claim 13, and in the specification, particularly at page 13, lines 5-7, and at lines 19-20.

New Claim 19 has been added directed to the method according to Claim 18 wherein the eating disorder associated with excessive food intake is obesity. Support for Claim 19 is found in original “Swiss-style” use Claim 14, and in the specification, particularly at page 13, lines 20-21.

New Claim 20 has been added directed to a method for preventing obesity in a person at risk therefor comprising administration to the person of about 0.001 mg/kg to about 100 mg/kg of a compound according to Claim 1. Support for Claim 20 is found in original “Swiss-style” use Claim 15, and in the specification, particularly at page 13, lines 23-25.

Serial No.: To be Assigned
Case No.: 21537YP
Page No.: 20

These amendments are fully supported by the specification and claims as originally filed and do not add new matter to the present application.

Applicants respectfully contend that the application is allowable, and a favorable response from the Examiner is earnestly solicited.

Respectfully submitted,

By



Catherine D. Fitch, Reg. No. 36,502
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel: (732)594-4283

April 19, 2006